MMSET promotes t(4;14)-positive MM ferroptosis sensitivity via ACSL4 in vivo. (A) A schematic diagram of the xenograft model. NCI-H929 cells with MMSET knockdown (shM) or without knockdown (shNC) were injected subcutaneously into NOD SCID mice to establish a xenograft model. When tumor volumes (vol.) reached ∼50 to 80 mm3, the mice were randomized to receive solvent control (vehicle) or RSL3 (10 mg/kg) IP for 3 weeks (n = 5). (B) Growth curves of the xenograft tumors. Tumor volumes of each group were calculated every 3 days. (C) Weights of the xenograft tumors. Tumor weights of each group were analyzed on the day of mice euthanasia. (D) Immunohistochemical analysis of ki-67, MMSET, ACSL4, and 4-HNE protein levels in tumor tissues from the 4 groups of mice with the indicated treatment. Scale bar: 100 μm. (E) Expression levels of targeted proteins in mice of the treatment groups were quantitatively analyzed using Image J. ns, not significant; P > .05, ∗ P < .05, ∗∗ P < .01, and ∗∗∗ P < .001.
